Description
Methods are provided for modulating the activity of p53 tumor suppressor protein by affecting p53 translational regulation. The methods involve affecting the function of a p53 5’-untranslated region (5’UTR), including its interaction with proteins such as Ribosomal Protein L26 (RPL26), nucleolin, and p53. Use of RPL26 siRNA to downregulate p53 induction is shown. These methods can be developed for treatment of cancer, neurodegenerative disorders and minimizing the negative effects of cellular stresses.
Keywords
p53, nucleolin, RPL26
Granted Patents or Published Applications
US Publication No. 2009/0149377
Related Scientific References
Chen, J. et al., “Interactions of nucleolin and ribosomal protein L26 (RPL26) in the translational control of human p53”, J. Biol. Chem. (Epub. Mar. 20, 2012);
Takagi, M. et al., “Regulation of p53 translation and induction after DNA damage by ribosomal protein L26 and nucleolin”, Cell 123: 49-63 (Oct. 6, 2005).
Licensing Opportunities
We are currently seeking licensing opportunities in all fields for the development of this technology. Contact: chad.riggs@stjude.org
Related Links
- Activation of Prodrugs by Carboxylesterase (SJ-98-0001)
- Anti-GD2-BB-zeta Chimeric Receptor for Treating GD2+ Malignancies (SJ-13-0035)
- Antibodies to Tim4 for use as an Immune Enhancer and Cancer Therapeutic (SJ-18-0006)
- Association of Neuraminidase Regulated Exocytosis with Cancer Metastasis (SJ-11-0012)
- B7-H3-CAR 41BB ligand co-stimulation for solid tumors (SJ-19-0014)
- BCRP/ABCG2 as Stem Cell Marker (SJ-97-0016)
- CD33 CAR (SJ-17-0010)
- CD7 CAR placed in CD7neg memory cells (SJ-15-0020)
- Chimeric gene and protein that can be used to create Optogranules: Light induced stress granules (SJ-18-0010)
- Chimeric IL13-MyD88 and PDL1-MyD88 receptors (SJ-20-0032)
- Development and Optimization of a Serotype-Independent Method of Adeno-Associated Virus (AAV) Harvest and Purification (SJ-16-0036)
- DNA Methylation Profile and Biomarkers for identifying functional T-cells (SJ-17-0002)
- DNMT3a knockout CAR T cells with Antigen Specificity (for solid tumors) (SJ-19-0024)
- Efficient generation of T-Cell Receptor (TCR) sequences in response to a variety of immune responses (SJ-19-0017)
- Erythroid Specific Promoter for Hematopoietic Disorders (SJ-16-0040)
- Extradomain-B Fibronectin (EDB)-targeted CAR Immune Cell Therapy (SJ-19-0029)
- Fibcd1 to treat or prevent muscle wasting (SJ-20-0008)
- Gene Therapy for Wiskott-Aldrich Syndrome (SJ-19-0012)
- Generation of Therapeutic T Cell Receptors for Fibrolamellar Cancer (SJ-19-0046)
- GMCSF.IL18 chimeric cytokine receptor for solid tumors (SJ-19-0028)
- GRP78 targeted adoptive cell therapy for surface GRP78+ (pediatrics and adult) cancer (SJ-19-0050)
- HMGA2 in Gene Therapy Vectors (SJ-16-0014)
- Hybrid Compounds to treat Gastrointestinal Infections (SJ-14-0019/UTA 14-01)
- IL35 Receptor (SJ-08-0039)
- Immune Cells with DNMT3A Gene Modifications (SJ-16-0009)
- Improved GD2 Ab for Neuroblastoma (SJ-17-0017)
- Improved Method to Produce Proteins to Treat Lysosomal Storage Disorders (SJ-01-0020)
- Interleukin-35 (IL-35) (SJ-06-0016)
- MAGE-A11 Inhibitor for cancer (SJ-20-0033)
- Method for Enhancing Recombinant Antibody Production (SJ-08-0032)
- Method for predicting T-cell development stage (and therapy success) (SJ-19-0033)
- Minimized Liver Specific Promoter for Improved Gene Expression in Gene Therapy Vectors (SJ-04-0024)
- miRNAs for Treating Cerebral Ventricle Enlargement in Schizophrenia Patients (SJ-19-0039)
- Myd88 and CD40 Costimulatory Domains for Chimeric Antigen Receptors (SJ-18-0021)
- New Method for Differentiating T-cells (SJ-18-0019)
- p53 Inhibitory Oligonucloeotides (SJ-09-0015)
- Protease Serine 21 (PRSS21) Targeted Immunotherapies (SJ-18-0043)
- Rapid Cloning of T Cell Receptors (SJ-16-0001)
- REGNASE-1 Gene Knockout or BATF Overexpression for Improving T-cell Function (SJ-19-0027, SJ-20-0007)
- RIPK3 Fusion Protein for Treating Cancer and Autoimmunity (SJ-12-0036)
- Safety Test for Gene Therapy Vectors (SJ-15-0027)
- Use of Amylase or Maltose to Treat or Prevent Neurodegeneration (SJ-20-0009)
- Use of IL13 Promoter to Express Therapeutic Genes (SJ-18-0042)
Contact the Office of Technology Licensing (Phone: 901-595-2342, Fax: 901-595-3148) for more information.